Moderna (MRNA) Tops Q4 EPS by 5c

Moderna (NASDAQ: MRNA) reported Q4 EPS of ($0.37), $0.05 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $14.06 million versus the consensus estimate of $17.37 million.

“The Moderna team continues to execute our strategy, including our CMV Phase 2 study enrolling ahead of plan, shipping the coronavirus Phase 1 clinical materials to NIH/NIAID in just 42 days, and announcing five new development candidates in the last two months,” said Stéphane Bancel, Moderna’s Chief Executive Officer. “We have up to $2 billion of capital to invest in the Company, a great team, a powerful mRNA platform and a state-of-the-art manufacturing site. I am more energized than ever about our future.”

Reiterating Financial Guidance

• Moderna expects net cash used in operating activities and for purchases of property and equipment in 2020 to be similar to 2019, between $490 million and $510 million.

For earnings history and earnings-related data on Moderna (MRNA) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Arvinas CMO to depart in July as company begins search
• People Inc. names new chief accounting officer as predecessor retires